Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BY 4.0Frontiers in Cardiovascular Medicine

The role of VWF/ADAMTS13 axis in COVID-19-associated coagulopathy

  • Quan Zhang1,2
  • Ye Tan3
  • Meijuan Peng1
  • Shangjie Wu4
  • X. Long Zheng2,5
5 affiliations
  1. 1Department of Pulmonary and Critical Care Medicine, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital)
  2. 2Departments of Pathology and Laboratory Medicine, The University of Kansas Medical Center
  3. 3Department of Pulmonary and Critical Care Medicine, Linxiang People’s Hospital
  4. 4Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital of Central South University
  5. 5Institute of Reproductive and Developmental Sciences, The University of Kansas Medical Center
Read full textPDFDOICite

Abstract

Coronavirus disease 2019, which broke out in 2019, is a disease caused by SARS-CoV-2 infection. Although this infection mainly affects the respiratory system, a high incidence of thrombotic events has been observed in severe or critically ill cases and in a considerable number of non-survivors of COVID-19. Although the coagulation dysfunction and hypercoagulability of COVID-19 have been reported in the literature, the specific situation of its coagulation function has not been fully studied. The observation of microvascular thrombosis in COVID-19 patients has attracted our attention to investigate the potential inflammatory endothelial injury or damage. Von Willebrand factor (VWF) and its proteolytic protease, A D isintegrin A nd M etalloproteinase with T hrombo S pondin type 1 motifs, 13 (ADAMTS13), play an important role in maintaining the vascular health and organ perfusion. Therapeutic and prophylactic anticoagulation are important measures to prevent these kinds of thrombotic events, but new treatments such as recombinant ADAMTS13 and anti-VWF nanobody Caplacizumab are being studied in vitro for thrombosis with high efficacy. This review focuses on the discussion of the current research progress of the treatment of COVID-19-associated coagulopathy by correcting the imbalance of VWF-ADAMTS13 axis, the existing problems, and the prospects.

Related

  1. SFTSV infection drives platelet-associated fibrinogen accumulation and platelet-mediated coagulopathy
    Chenhui Lin, Ling Xu, Chaoxiong Yue +13
    Research and practice in thrombosis and haemostasisPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. PO129 | CLINICAL BENEFIT OF RECOMBINANT ADAMTS13 IN CTTP ASSOCIATED WITH HOMOZYGOUS PD173G MUTATION AND UNDETECTABLE ACTIVITY
    Raimondo De Cristofaro
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  3. Risk prediction model for pegaspargase-associated severe coagulopathy and blood product costs: a single-center retrospective cohort study.
    Xiangyu Ding, Zhonghao Xu, Chenhong Jia +2
    Frontiers in pharmacologyPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref
  4. Associated factors and dynamic coagulation changes of cefoperazone/sulbactam-associated coagulopathy: a retrospective case-control study from a single-center real-world ADR database
    Minghui Zhang, Lingrong Zeng, Jiawu Xiong +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  5. Beyond Neuroinflammation: Targeting the Microbe–Barrier–Brain Axis Through Precision Nutrition in Neurological Long COVID (Neuro-PASC)
    Amador Velázquez De Castro-Bono, Gracia Castro-Luna, José Luis Guil-Guerrero
    NutrientsPeer-reviewedCC BY 4.0Full textNeurologyCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{zhang2026role,
  title = {{The role of VWF/ADAMTS13 axis in COVID-19-associated coagulopathy}},
  author = {Quan Zhang and Ye Tan and Meijuan Peng and Shangjie Wu and X. Long Zheng},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  month = oct,
  doi = {10.3389/fcvm.2026.1981718},
  url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1981718/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - The role of VWF/ADAMTS13 axis in COVID-19-associated coagulopathy
AU  - Quan Zhang
AU  - Ye Tan
AU  - Meijuan Peng
AU  - Shangjie Wu
AU  - X. Long Zheng
PY  - 2026
DA  - 2026/10/13
JO  - Frontiers in Cardiovascular Medicine
DO  - 10.3389/fcvm.2026.1981718
UR  - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1981718/full
AB  - Coronavirus disease 2019, which broke out in 2019, is a disease caused by SARS-CoV-2 infection. Although this infection mainly affects the respiratory system, a high incidence of thrombotic events has been observed in severe or critically ill cases and in a considerable number of non-survivors of COVID-19. Although the coagulation dysfunction and hypercoagulability of COVID-19 have been reported in the literature, the specific situation of its coagulation function has not been fully studied. The observation of microvascular thrombosis in COVID-19 patients has attracted our attention to investigate the potential inflammatory endothelial injury or damage. Von Willebrand factor (VWF) and its proteolytic protease, A D isintegrin A nd M etalloproteinase with T hrombo S pondin type 1 motifs, 13 (ADAMTS13), play an important role in maintaining the vascular health and organ perfusion. Therapeutic and prophylactic anticoagulation are important measures to prevent these kinds of thrombotic events, but new treatments such as recombinant ADAMTS13 and anti-VWF nanobody Caplacizumab are being studied in vitro for thrombosis with high efficacy. This review focuses on the discussion of the current research progress of the treatment of COVID-19-associated coagulopathy by correcting the imbalance of VWF-ADAMTS13 axis, the existing problems, and the prospects.
SN  - 2297-055X
ER  -